![](https://endpts.com/wp-content/uploads/2021/07/Bernat-Olle-Vedanta-tile-scaled.jpg)
Bernat Olle, Vedanta Biosciences CEO
Pfizer-backed Vedanta Biosciences lands $106M for PhIII in C. diff, PhII in IBD
Vedanta Biosciences has secured the cash it needs to run a Phase III in Clostridioides difficile and a mid-stage trial in ulcerative colitis, with runway …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.